Nu Skin Enterprises, Inc. (NUS) Income Statement

The consistency of the declines matters more than any single quarter: there is no reported period of stabilization to suggest the erosion is episodic, and the 2026Q2 print of -17.1% is actually the steepest drop in the series, which reads as re-acceleration rather than bottoming. Revenue has fallen from $445.6M in 2024Q4 to $320.1M, a roughly 28% cumulative loss in seven quarters, implying that the topline problem is compounding even as the cost base is being reduced.

The scale of the SG&A reduction suggests management has treated the revenue decline as structural rather than temporary, cutting roughly $88M of annualized overhead in seven quarters. However, because the ratio improvement is only about two percentage points, the trimming has largely tracked revenue down rather than ahead of it, meaning fixed-cost leverage has not yet been rebuilt. Investors should monitor whether further reductions can be achieved without eroding the selling infrastructure that a distributor-dependent model relies on.

The prior five quarters had shown a tentative normalization pattern, with operating margins holding in the 5.9% to 8.0% band through mid-2025, so the 2026Q2 break below zero represents a reversal of that recovery rather than a continuation of it. Notably, this occurred alongside a gross margin that held at 68.2% and SG&A that fell to its lowest level in the series, which suggests the loss was not driven by unit economics deteriorating or overhead re-expanding. The implication is that something below the gross profit line or outside normal operating expense recognition drove the quarter, warranting closer examination of the reported expense composition.